-
Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical Trial
Coerver, E. M. E., Fung, W. H., de Beukelaar, J., Bouvy, W. H., Canta, L. R., Gerlach, O. H. H., Hoitsma, E., Hoogervorst, E. L. J., de Jong, B. A., Kalkers, N. F., van Kempen, Z. L. E., Lövenich, H., van Munster, C. E. P., van Oosten, B. W., Smolders, J., Vennegoor, A., Zeinstra, E. M. P. E., Barrantes-Cepas, M., Kooij, G. & Schoonheim, M. M. & 8 others, , 9 Dec 2024, (E-pub ahead of print) In: JAMA Neurology.Research output: Contribution to journal › Article* › Academic › peer-review
-
The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis
Coerver, E., Schoof, L., Hogenboom, L., Wessels, M., van Ruyven, P., van Samkar, A., Mostert, J., van Kempen, Z., van Oosten, B. W., Wokke, B. H., Tallantyre, E., Myhr, K. M., Torkildsen, O., Killestein, J., Smets, I. & Strijbis, E., 1 Nov 2024, In: Multiple Sclerosis and Related Disorders. 91, 105900.Research output: Contribution to journal › Article* › Academic › peer-review
-
Aging is associated with reduced inflammatory disease activity independent of disease duration in relapsing multiple sclerosis trial populations
Coerver, E. M., Kaçar, S., Ciccarelli, O., Sormani, M. P., Barkhof, F., Arnold, D. L., Schoonheim, M. M., Van Kempen, Z. L., Mostert, J., Koch, M. W., Killestein, J., Eshaghi, A., Uitdehaag, B. M. & Strijbis, E. M., 8 Sept 2024, (E-pub ahead of print) In: Multiple sclerosis (Houndmills, Basingstoke, England). p. 13524585241272938Research output: Contribution to journal › Article* › Academic › peer-review
- All publications
